Show
Sort by
-
- Journal Article
- A1
- open access
Real-life effectiveness of mepolizumab in severe asthma : a systematic literature review
-
Personalized medicine for allergy treatment : allergen immunotherapy still a unique and unmatched model
-
- Journal Article
- A1
- open access
ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020)
-
SNOT-22 items and association with objective measures in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from SINUS-24 and SINUS-52 trials
-
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps : a systematic review for the EAACI guidelines
-
COVID‐19 pandemic : practical considerations on the organization of an allergy clinic : an EAACI/ARIA position paper
-
- Journal Article
- A1
- open access
Eosinophilic and noneosinophilic asthma : an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort
-
- Journal Article
- A1
- open access
Association between a type 2 inflammatory disease burden score and outcomes among patients with asthma
-
3TR : a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD
-
- Journal Article
- A1
- open access
Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care